Provided by Tiger Trade Technology Pte. Ltd.

Aytu BioScience, Inc.

2.37
+0.09003.95%
Post-market: 2.370.00000.00%19:30 EDT
Volume:52.35K
Turnover:123.80K
Market Cap:25.44M
PE:-0.71
High:2.40
Open:2.25
Low:2.22
Close:2.28
52wk High:3.07
52wk Low:1.65
Shares:10.73M
Float Shares:3.30M
Volume Ratio:1.32
T/O Rate:1.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3600
EPS(LYR):-2.1596
ROE:-97.42%
ROA:-3.66%
PB:0.72
PE(LYR):-1.10

Loading ...

Aytu Biopharma - Co and Lannett Terminate Metadate Agreement Effective June 23, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 26

Aytu Biopharma - to Continue Selling Existing Metadate Inventory and Pay Royalties Until Sales Cease - SEC Filing

THOMSON REUTERS
·
Jun 26

Aytu BioPharma Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Jun 11

Aytu BioPharma to present at Planet MicroCap Las Vegas 2026 investor conference fireside Q&A

Reuters
·
Jun 02

Aytu BioPharma to present at Lytham Partners Spring Investor Conference

Reuters
·
May 19

Analysts Offer Insights on Healthcare Companies: Assertio Therapeutics (ASRT), Aytu BioScience (AYTU) and Oruka Therapeutics (ORKA)

TIPRANKS
·
May 14

Aytu Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 14

Aytu Biopharma posts corporate presentation highlighting CNS portfolio, including EXXUA for depression

Reuters
·
May 14

Aytu BioPharma Q3 revenue falls amid EXXUA launch

Reuters
·
May 14

Aytu Biopharma FY26 Q3 turns to $5.6 million net loss; revenue drops to $12.4 million

Reuters
·
May 14

Aytu BioPharma Q3 EPS $(0.53) Misses $(0.51) Estimate, Sales $12.411M Beat $12.053M Estimate

Benzinga Earnings
·
May 14

Aytu Biopharma Q3 Adjusted Ebitda USD -2.8 Million

THOMSON REUTERS
·
May 14

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 13

Aytu Biopharma Inc expected to post a loss of 51 cents a share - Earnings Preview

Reuters
·
May 12

Aytu BioPharma to report fiscal Q3 results, host conference call after market close

Reuters
·
May 07

Aytu Biopharma presentation spotlights EXXUA launch for major depressive disorder growth strategy

Reuters
·
Apr 04

Aytu Biopharma issues amended warrants in unregistered exchange to restore equity classification

Reuters
·
Apr 03

Aytu Biopharma publishes investor presentation on its CNS-focused prescription portfolio and EXXUA for major depressive disorder

Reuters
·
Mar 18